reports
Adverum Biotechnologies Inc: 2 directors
Two Directors at Adverum Biotechnologies Inc bought 178,699 shares at between 4.220USD and 4.304USD. The significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Adverum Reminds Stockholders to Tender their Shares into the Offer by ...
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a Liquidation REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and Com...
- Jacob Mekhael
Merus Petosemtamab phase 2 mCRC results show high response rates
Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer De...
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
After 5.5-months, the S&P 500 (SPX) finally broke below its 20-day MA in decisive fashion on Friday. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay that way as long as the SPX holds abov...
NEM NEWMONT CORPORATION
FNV. FRANCO-NEVADA CORPORATION
ENS ENERSYS
AGI. ALAMOS GOLD INC.
ABX. BARRICK GOLD CORPORATION
K. KINROSS GOLD CORPORATION
BTO B2GOLD CORP.
IMG. IAMGOLD CORPORATION
BVN... COMPANIA DE MINAS BUENAVENTURA SAA SPONSORED ADR
ELD ELDORADO GOLD CORPORATION
EOSE EOS ENERGY ENTERPRISES INC (A)
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Merus Announces Publication of an Abstract on Petosemtamab in Metastat...
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Bicloni...
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract ...
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Lewi
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listi...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 16,860 shares of common stock and restricted stock units (RSUs) for 8,430 shares of common stock to two new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into ...
Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus to Present at the 2025 Wells Fargo Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET. The webcast of the presentation will be contemporaneously ava...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results ...
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H 2027 - LUNA 2-year long-term follow-up data planned in 4Q 2025 - Announced $10 million private placement with Frazier Life Sciences REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt un...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung – Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 % bei 43 auswertbaren Patienten und eine Gesamtüberlebensrate von 79 % nach 12 Monaten – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln und Barmitteläquivalenten, einschließlich des erfolgreichen Börsengangs mit ei...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités - Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 % et un taux de survie globale de 79 % à 12 mois - D’après le plan d’exploitation actuel de la société, la trésorerie et les équivalents de trésorerie existants, notamment le produit brut de 345 millions de dollars réalisé à l’issue d’une offre publique réussie et les titres négociables devr...
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annu...
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT. A live webcast of the fireside chat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.